Primaquine phosphate: Difference between revisions
| Line 10: | Line 10: | ||
==US Brand Names== | ==US Brand Names== | ||
PRIMAQUINE PHOSPHATE | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 04:52, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Primaquine (or primaquine phosphate) is a medication used in the treatment of malaria and Pneumocystis pneumonia. It is a member of the 8-aminoquinoline group of drugs that includes tafenoquine and pamaquine. Primaquine was first synthesised by Robert Elderfield of Columbia University in the 1940's.[1]
Category
Antimalarial
US Brand Names
PRIMAQUINE PHOSPHATE
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Primaquine blocks transport by inhibiting the formation of functional transport vesicles. Studies in a cell-free assay of protein transport through the Golgi apparatus.[2]
References
- ↑ Edgcomb JH, Arnold J, Young EH; et al. (1950). "Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report". Journal National Malaria Society. 9 (4): 285&ndash, 92. PMID 14804087.
- ↑ "Primaquine blocks transport by inhibiting the fo... [J Biol Chem. 1991] - PubMed - NCBI".